|Other names: Neurogenic bladder dysfunction|
|Symptoms||Sudden need to pee, frequency urination, leakage of urine following a strong urge, spontaneous leakage of urine, inability to pass urine|
|Complications||Urinary tract infections, incontinence, kidney stones, vesicoureteral reflux|
|Causes||Spinal cord injury, multiple sclerosis, cerebral palsy, traumatic brain injury, Parkinson's disease, dementia, normal-pressure hydrocephalus, childbirth, Guillain–Barré syndrome|
|Diagnostic method||Urodynamic testing, medical imaging, electroencephalograph (EEG), electromyograph (EMG)|
|Treatment||Depends on cause and symptoms|
|Medication||Oxybutynin, tolterodine, imipramine, tamsulosin|
Neurogenic bladder refers to urinary bladder problems due to dysfunction of the nervous system. Symptoms can include an overactive bladder with the sudden need to pee, frequency urination, and leakage of urine following a strong urge to pee; spontaneous leakage of urine; and inability to pass urine. Complications may include urinary tract infections, incontinence, kidney stones, and vesicoureteral reflux.
Causes include spinal cord injury, multiple sclerosis, stroke, cerebral palsy, traumatic brain injury, Parkinson's disease, dementia, normal-pressure hydrocephalus, childbirth, and Guillain–Barré syndrome. Diagnosis may be based on urodynamic testing, medical imaging, electroencephalograph (EEG), and electromyograph (EMG).
Treatment depends on underlying cause and the presenting symptoms. An overactive bladder is often managed by clean intermittent catheterization and anticholinergic agents such as oxybutynin. Other options may include bladder training, alpha-blockers such as tamsulosin, and sacral nerve stimulation. Spontaneous leakage may be improved with Kegel exercises. A suprapubic catheter may be required if a urinary catheter will not pass.
Neurogenic bladder occurs in about 65% of people with multiple sclerosis, 55% of people with Parkinson's, 15% of people with stroke, 75% of people with spinal cord injury, and nearly all people with spina bifida. Around 400 BC the condition was described by Hippocrates following spinal cord injury. Urinary catheterization was determined to be a useful treatment during World War II.
There are different types of neurogenic bladder depending on the underlying cause. Many of these types may have similar symptoms.
Uninhibited bladder is usually due to damage to the brain from a stroke or brain tumor. This can cause reduced sensation of bladder fullness, low capacity bladder and urinary incontinence. Unlike other forms of neurogenic bladder, it does not lead to high bladder pressures that can cause kidney damage.
In spastic neurogenic bladder (also known as upper motor neuron or hyper-reflexive bladder), the muscle of the bladder (detrusor) and urethral sphincter do not work together and are usually tightly contracted at the same time. This phenomenon is also called detrusor external sphincter dyssynergia (DESD). This leads to urinary retention with high pressures in the bladder that can damage the kidneys. The bladder volume is usually smaller than normal due to increased muscle tone in the bladder. Spastic neurogenic bladder is usually caused by damage to the spinal cord above the level of the 10th thoracic vertebrae (T10).
In flaccid bladder (also known as lower motor neuron or hypotonic bladder), the muscles of the bladder lose ability to contract normally. This can cause the inability to void urine even if the bladder is full and cause a large bladder capacity. The internal urinary sphincter can contract normally, however urinary incontinence is common. This type of neurogenic bladder is caused by damage to the peripheral nerves that travel from the spinal cord to the bladder.
Mixed type of neurogenic bladder can cause a combination of the above presentations. In mixed type A, the bladder muscle is flaccid but the sphincter is overactive. This creates a large, low pressure bladder and inability to void, but does not carry as much risk for kidney damage as a spastic bladder. Mixed type B is characterized by a flaccid external sphincter and a spastic bladder causing problems with incontinence.
Signs and symptoms
Neurogenic bladder can cause a range of urinary symptoms including urinary urgency, urinary incontinence or difficulty urinating (urinary retention.) The first sign of bladder dysfunction may be recurrent urinary tract infections (UTIs).
Neurogenic bladder can cause hydronephrosis, recurrent urinary tract infections, and recurrent kidney stones which may compromise kidney function. This is especially significant in spastic neurogenic bladder that leads to high bladder pressures. Kidney failure was previously a leading cause of mortality in patients with spinal cord injury but is now dramatically less common due to improvements in bladder management.
Urine storage and elimination (urination) requires coordination between the bladder emptying muscle (detrusor) and the external sphincter of the bladder. This coordination can be disrupted by damage or diseases of the central nervous system, peripheral nerves or autonomic nervous system. This includes any condition that impairs bladder signaling at any point along the path from the urination center in the brain, spinal cord, peripheral nerves and the bladder.
Central nervous system
Damage to the brain or spinal cord is the most common cause of neurogenic bladder. Damage to the brain can be caused by stroke, brain tumors, multiple sclerosis, Parkinson's disease or other neurodegenerative conditions. Bladder involvement is more likely if the damage is in the area of the pons. Damage to the spinal cord can be caused by traumatic injury, demyelinating disease, syringomyelia, cauda equina syndrome, or spina bifida. Spinal cord compression from herniated disks, tumor, or spinal stenosis can also result in neurogenic bladder.
Peripheral nervous system
Damage to the nerves that travel from the spinal cord to the bladder (peripheral nerves) can cause neurogenic bladder, usually the flaccid type. Nerve damage can be caused by diabetes, alcoholism, and vitamin B12 deficiency. Peripheral nerves can also be damaged as a complication of major surgery of the pelvis, such as for removal of tumors.
The diagnosis of neurogenic bladder is made based on a complete history and physical examination and may require imaging and specialized studies. History should include information on the onset, duration, triggers, severity, other medical conditions and medications (including anticholinergics, calcium channel blockers, diuretics, sedatives, alpha-adrenergic agonist, alpha 1 antagonists). Urinary symptoms may include frequency, urgency, incontinence or recurrent urinary tract infections (UTIs). Questionnaires can be helpful in quantifying symptom burden. In children it is important to obtain a prenatal and developmental history.
Ultrasound imaging can give information on the shape of the bladder, post-void residual volume, and evidence of kidney damage such as kidney size, thickness or ureteral dilation. A voiding cystourethrography study uses contrast dye to obtain images of the bladder both when it is full and after urination which can show changes in bladder shape consistent with neurogenic bladder.
Urodynamic studies are an important component of the evaluation for neurogenic bladder. Urodynamics refers to the measurement of the pressure-volume relationship in the bladder. The bladder usually stores urine at low pressure and urination can be completed without a dramatic pressure rise. Damage to the kidneys is probable if the pressure rises above 40 cm of water during filling. Bladder pressure can be measured by cystometry, during which the bladder is artificially filled with a catheter and bladder pressures and detrusor activity are monitored. Patterns of involuntary detrusor activity as well as bladder flexibility, or compliance, can be evaluated. The most valuable test to test for detrusor sphincter dyssynergia (DESD) is to perform cystometry simultaneously with external sphincter electromyography (EMG). Uroflowmetry is a less-invasive study that can measure urine flow rate and use it to estimate detrusor strength and sphincter resistance. Urethral pressure monitoring is another less-invasive approach to assessing detrusor sphincter dyssynergia. These studies can be repeated at regular intervals, especially if symptoms worsen or to measure response to therapies.
Imaging of the pelvis with CT scan or magnetic resonance imaging may be necessary, especially if there is concern for an obstruction such as a tumor. The inside of the bladder can be visualized by cystoscopy.
Treatment depends on the type of neurogenic bladder and other medical problems. Treatment strategies include catheterization, medications, surgeries or other procedures. The goals of treatment is to keep bladder pressures in a safe range and eliminate residual urine in the bladder after urination (post-void residual volumes).
Emptying the bladder with the use of a catheter is the most common strategy for managing urinary retention from neurogenic bladder. For most patients, this can be accomplished with intermittent catherization which involves no surgery or permanently attached appliances. Intermittent catheterization involves using straight catheters (which are usually disposable or single-use products) several times a day to empty the bladder. This can be done independently or with assistance. For people who are unable to use disposable straight catheters, a Foley catheter allows continuous drainage of urine into a sterile drainage bag that is worn by the patient but are associated with higher rates of complications.
Oxybutynin is a common anti-cholinergic medication used to reduce bladder contractions by blocking M3 muscarinic receptors in the detrusor. Its use is limited by side effects such as dry mouth, constipation and decreased sweating. Tolterodine is a longer acting anticholinergic that may have fewer side effects.
For urinary retention, cholinergics (muscarinic agonists) like bethanechol can improve the squeezing ability of the bladder. Alpha blockers can also reduce outlet resistance and allow complete emptying if there is adequate bladder muscle function.
Botulinum toxin (Botox) can be used through two different approaches. For spastic neurogenic bladder, the bladder muscle (detrusor) can be injected which will cause it to be flaccid for 6–9 months. This prevents high bladder pressures and intermittent catherization must be used during this time.
There are various strategies to alter the interaction between the nerves and muscles of the bladder, including nonsurgical therapies (transurethral electrical bladder stimulation), minimally invasive procedures (sacral neuromodulation pacemaker), and operative (reconfiguration of sacral nerve root anatomy).
Surgical interventions may be pursued if medical approaches have been maximized. Surgical options depend on the type of dysfunction observed on urodynamic testing, and may include:
- Urinary diversion: Creation of a stoma (from the intestines, called "conduit") that bypasses the urethra to empty the bladder directly through a skin opening. Several techniques may be used. One technique is the Mitrofanoff stoma, where the appendixor a portion of the ileum (‘Yang-Monti’ conduit) are used to create the diversion. The ileum and ascending colon can also be used to create a pouch accessible for catheterization (Indiana pouch).
- Urethral stents or urethral sphincterotomy are other surgical approaches that can reduce bladder pressures but require use of an external urinary collection device.
- Urethral slings may be used in both adults and children 
- Artificial urinary sphincter have shown good term outcomes in adults and pediatric patients. One study on 97 patients followed for a mean duration of 4 years found that 92% percent were continent at day and night during follow up. However, patients in this study who had intermediate-type bladders underwent adjuvent cystoplasty.
The overall prevalence of neurogenic bladder is limited due to the broad range of conditions that can lead to urinary dysfunction. Neurogenic bladder is common with spinal cord injury and multiple sclerosis. Rates of some type of urinary dysfunction surpass 80% one year after spinal cord injury. Among patients with multiple sclerosis, 20–25% will develop neurogenic bladder although the type and severity bladder dysfunction is variable.
- "Bladder Control Problems & Nerve Disease | NIDDK". National Institute of Diabetes and Digestive and Kidney Diseases. Retrieved 26 January 2021.
- Tayyeb, M; Tadi, P (January 2020). "Neurogenic Bladder". PMID 32809452. Cite journal requires
- Argyropolous, Spilios; Forshall, Sam; Nutt, David (2004). Life Care Planning and Case Management Handbook. CRC Press. p. 483. ISBN 978-0-203-50525-0.
- Fogel, Barry S.; Greenberg, Donna B. (2015). Psychiatric Care of the Medical Patient. Oxford University Press. p. PT3632. ISBN 978-0-19-022629-9.
- Dorsher PT, McIntosh PM (2012). "Neurogenic bladder". Advances in Urology. 2012: 816274. doi:10.1155/2012/816274. PMC 3287034. PMID 22400020.
- Amarenco, Gerard; Sheikh Ismaël, Samer; Chesnel, Camille; Charlanes, Audrey; LE Breton, Frederique (Dec 2017). "Diagnosis and clinical evaluation of neurogenic bladder". European Journal of Physical and Rehabilitation Medicine. 53 (6): 975–980. doi:10.23736/S1973-9087.17.04992-9. ISSN 1973-9095. PMID 29072046.
- Schurch, Brigitte; Tawadros, Cécile; Carda, Stefano (2015). "Dysfunction of lower urinary tract in patients with spinal cord injury". Handbook of Clinical Neurology. 130: 247–267. doi:10.1016/B978-0-444-63247-0.00014-6. ISBN 9780444632470. ISSN 0072-9752. PMID 26003248.
- Bacsu, Chasta-Dawne; Chan, Lewis; Tse, Vincent (2012). "Diagnosing detrusor sphincter dyssynergia in the neurological patient". BJU International. 109 Suppl 3: 31–34. doi:10.1111/j.1464-410X.2012.11042.x. ISSN 1464-410X. PMID 22458490.
- Sripathi, Venkataramani; Mitra, Aparajita (2017-07-01). "Management of Neurogenic Bladder". The Indian Journal of Pediatrics. 84 (7): 545–554. doi:10.1007/s12098-017-2356-7. ISSN 0973-7693. PMID 28553689.
- Stoffel, John T. (2016). "Detrusor sphincter dyssynergia: a review of physiology, diagnosis, and treatment strategies". Translational Andrology and Urology. 5 (1): 127–135. doi:10.3978/j.issn.2223-4683.2016.01.08. ISSN 2223-4691. PMC 4739973. PMID 26904418.
- Ludwikowski, Barbara M.; Bieda, Jan-Christoph; Lingnau, Anja; González, Ricardo (2019). "Surgical Management of Neurogenic Sphincter Incompetence in Children". Frontiers in Pediatrics. 7: 97. doi:10.3389/fped.2019.00097. ISSN 2296-2360. PMC 6448010. PMID 30984720.
- Myers, Jeremy B.; Mayer, Erik N.; Lenherr, Sara (February 2016). "Management options for sphincteric deficiency in adults with neurogenic bladder". Translational Andrology and Urology. 5 (1): 145–157. doi:10.3978/j.issn.2223-4683.2015.12.11. ISSN 2223-4691. PMC 4739985. PMID 26904420.
- Bersch, Ulf; Göcking, Konrad; Pannek, Jürgen (2009-03-01). "The Artificial Urinary Sphincter in Patients with Spinal Cord Lesion: Description of a Modified Technique and Clinical Results". European Urology. 55 (3): 687–695. doi:10.1016/j.eururo.2008.03.046. ISSN 0302-2838. PMID 18394784.
- Singh, G.; Thomas, D. G. (February 1996). "Artificial urinary sphincter in patients with neurogenic bladder dysfunction". British Journal of Urology. 77 (2): 252–255. doi:10.1046/j.1464-410x.1996.85515.x. ISSN 0007-1331. PMID 8800894.